Case Study

Meridian Builds Robust Gene Therapy Research Program

Leveraging Advarra’s Integrated IRB and IBC Services

Partnering with Advarra’s Institutional Biosafety Committee, Meridian Clinical Research established a program for conducting clinical trials with cutting edge, genetically engineered vaccines. Eight sites partnered with Advarra’s central IRB and IBC to ensure the safety of trial participants, as well as site staff when conducting gene therapy research. This collaboration resulted in Meridian averaging four-day turnaround time IBC approvals. As a result of Meridian’s comprehensive and robust program, they were among the first sites to obtain approval for a large Phase III COVID-19 vaccine study under Operation Warp Speed (OWS).

Fill out the form to download the case study.

Who should watch?

text goes here

CEU Credits

text goes here

Certificate of Attendance

text goes here

Time: 1 p.m. ET, 12 p.m. CT, 10 a.m. PT
Duration: 1 hour

Access Now